Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cnossen

Showing results (261-270 of 442) with videos related to

Pageof 45
Sort By:
Pediatric Research|December 13, 2024
Home phototherapy for neonatal hyperbilirubinemia: current practices and attitudesMaryse C Cnossen, Jessie Spaan, Maria S Fleischmann, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 12, 2012
Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failureTrijntje T Cnossen, Jeroen P Kooman, Harmen P Krepel, et al.
Journal of the American Chemical Society|September 10, 2009
Probing flexibility in porphyrin-based molecular wires using double electron electron resonanceJanet E Lovett, Markus Hoffmann, Arjen Cnossen, et al.
Orphanet Journal of Rare Diseases|October 24, 2020
Novel GANAB variants associated with polycystic liver diseaseLiyanne F M van de Laarschot, René H M Te Morsche, Alexander Hoischen, et al.
Haematologica|July 9, 2016
A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patientsHendrika Hazendonk, Karin Fijnvandraat, Janske Lock, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2024
Pharmacokinetic-Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII ConcentrateLars L F G Valke, Michael E Cloesmeijer, Hassan Mansouritorghabeh, et al.
Blood Advances|December 14, 2019
von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWDFerdows Atiq, Lisette M Schütte, Agnes E M Looijen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 28, 2020
Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort studyCaroline S B Veen, Elise J Huisman, Marjon H Cnossen, et al.
Kidney360|August 21, 2025
Clinical Frailty Scale, Surprise Question and One-year Mortality in Older Patients With Advanced CKDImre Demirhan, Micha Jongejan, Mathijs van Oevelen, et al.
BMJ Open|February 16, 2022
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN studyJessica M Heijdra, Wala Al Arashi, Nico C B de Jager, et al.
Pageof 45

Showing results (261-270 of 442) with videos related to

Sort By:
Pageof 45
Pediatric Research|December 13, 2024
Home phototherapy for neonatal hyperbilirubinemia: current practices and attitudesMaryse C Cnossen, Jessie Spaan, Maria S Fleischmann, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 12, 2012
Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failureTrijntje T Cnossen, Jeroen P Kooman, Harmen P Krepel, et al.
Journal of the American Chemical Society|September 10, 2009
Probing flexibility in porphyrin-based molecular wires using double electron electron resonanceJanet E Lovett, Markus Hoffmann, Arjen Cnossen, et al.
Orphanet Journal of Rare Diseases|October 24, 2020
Novel GANAB variants associated with polycystic liver diseaseLiyanne F M van de Laarschot, René H M Te Morsche, Alexander Hoischen, et al.
Haematologica|July 9, 2016
A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patientsHendrika Hazendonk, Karin Fijnvandraat, Janske Lock, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2024
Pharmacokinetic-Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII ConcentrateLars L F G Valke, Michael E Cloesmeijer, Hassan Mansouritorghabeh, et al.
Blood Advances|December 14, 2019
von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWDFerdows Atiq, Lisette M Schütte, Agnes E M Looijen, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 28, 2020
Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort studyCaroline S B Veen, Elise J Huisman, Marjon H Cnossen, et al.
Kidney360|August 21, 2025
Clinical Frailty Scale, Surprise Question and One-year Mortality in Older Patients With Advanced CKDImre Demirhan, Micha Jongejan, Mathijs van Oevelen, et al.
BMJ Open|February 16, 2022
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN studyJessica M Heijdra, Wala Al Arashi, Nico C B de Jager, et al.
Pageof 45